8-K current report · filed Nov 10, 2026

Protalix BioTherapeutics, Inc. (PLX) 8-K Current Report: November 10, 2026

Item 2.02Item EX-99.1PLX overview

Short answer

Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Protalix’s quarter ended September 30, 2026.

Protalix BioTherapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Protalix’s quarter ended September 30, 2026
  • Business and clinical updates accompany the quarterly financial results
  • Investors should review Exhibit 99.1 for financial figures and pipeline developments

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $21.9M and net income $4.0M, up from $17.9M and $2.4M year over year
  • Nine-month revenue $75.6M, including $25.0M Chiesi milestone, versus $43.6M in 2025
  • Nine-month net income $26.1M, or $0.31 diluted EPS, versus $1.1M net loss previously
  • Cash, equivalents, and short-term deposits $48.5M, with no outstanding debt or warrants
  • 2026 revenue guidance reaffirmed at approximately $78.0M to $83.0M, while PRX-115 Phase 2 results remain expected in the second half of 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Protalix BioTherapeutics, Inc. 8-K filings

Get the next PLX 8-K as it lands

Follow PLX for push alerts, or ask the research agent what this filing means.